Abstract: Injectable hydrogels in the form of crosslinked nano beads or particle in the size range 5 nm to 10 ?m, comprising PAMAM dendrimer with asymmetrical peripheral end groups such that one of the terminal groups is involved in formation of hydrogel and the other in involved in the conjugation of drugs or imaging agents are formed by reaction of the PAMAM dendrimer with asymmetrical end groups with linear, branched, hyperbranched or star shaped polymers with functionalized terminal groups. The PAMAM dendrimer with asymmetrical terminal groups consists of a Generation 2 and above PAMAM dendrimer with symmetrical end groups modified using the amino acids or their modified forms. The gel is formed as small crosslinked particles in the size range 25 nm to 10 ?m and is suitable for injectable delivery of hydrogel or ocular delivery for the purpose of therapeutic treatment and imaging.
Type:
Grant
Filed:
September 27, 2016
Date of Patent:
September 20, 2022
Assignees:
Wayne State University, The United States of America, as Represented by the Secretary, Department of Health and Human Services
Abstract: The invention provides an adeno-associated viral (AAV) vector comprising a capsid comprising the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 9, wherein the AAV vector further comprises a heterologous nucleic acid sequence, and wherein the heterologous nucleic acid sequence can encode the NGF-PTH fusion polypeptide or methylmalonyl CoA mutase enzyme. The invention also provides a polypeptide comprising nerve growth factor (NGF) signal peptide and parathyroid hormone (PTH), wherein the polypeptide can comprise, consist essentially of, or consist of the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2. The invention provides a nucleic acid encoding the polypeptide, a vector comprising the nucleic acid, and a composition comprising the polypeptide, nucleic acid, or vector, as well as treatment methods comprising the polypeptide, nucleic acid, vector, or composition.
Type:
Grant
Filed:
May 12, 2016
Date of Patent:
September 20, 2022
Assignee:
The United States of America,as represented by the Secretary, Department of Health and Human Service
Inventors:
John A. Chiorini, Giovanni Di Pasquale, Randy Chandler, Charles P. Venditti
Abstract: High efficiency methods for producing retinal pigment epithelial cells from induced pluripotent stem cells (iPSCs) are disclosed herein. The iPSCs are produced from somatic cells, including retinal pigment epithelial (RPE) cells, such as fetal RPE stem cells. In some embodiments, the iPSC include a tyrosinase promoter operably linked to a marker. Methods are disclosed for using the RPE cells, such as for treatment. Methods for screening for agents that affect RPE differentiation are also disclosed.
Type:
Grant
Filed:
September 27, 2019
Date of Patent:
September 13, 2022
Assignee:
THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
Inventors:
Kapil Bharti, Janine Davis, Arvydas Maminishkis, Sheldon S. Miller
Abstract: The present is directed to compositions comprising regulatory T cell epitopes, wherein said epitopes comprise a polypeptide comprising at least a portion of SEQ NOS: 1-14, fragments and/or variants thereof, as well as methods of producing and using the same.
Type:
Grant
Filed:
October 5, 2018
Date of Patent:
September 13, 2022
Assignees:
EpiVax Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services Food and Drug Administration
Abstract: The invention provides a method of inhibiting a malignancy associated with human papilloma virus (HPV) comprising administering to a subject an agent that blocks PD-L1 and TGF-beta pathways, thereby inhibiting a malignancy associated with HPV in the subject.
Type:
Grant
Filed:
May 8, 2018
Date of Patent:
September 13, 2022
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Julius Y. Strauss, James L. Gulley, Christian S. Hinrichs
Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of thyroglobulin (TG), TG470-478. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
Type:
Grant
Filed:
September 27, 2019
Date of Patent:
September 13, 2022
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Kenichi Hanada, Qiong J. Wang, James C. Yang, Zhiya Yu
Abstract: Provided are methods of producing an isolated population of cells for adoptive cell therapy comprising use of at least one cell permeable Ca2+ dye. Further embodiments of the invention provide isolated populations of cells produced by the methods, related pharmaceutical compositions, and related methods of treating or preventing cancer in a patient.
Type:
Application
Filed:
September 18, 2020
Publication date:
September 8, 2022
Applicant:
THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES
Inventors:
Douglas C. Palmer, Anna Pasetto, Nicholas P. Restifo, Steven A. Rosenberg
Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E711-19. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
Type:
Grant
Filed:
November 23, 2020
Date of Patent:
September 6, 2022
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Christian S. Hinrichs, Steven A. Rosenberg
Abstract: RNA aptamers are disclosed with distinct fluorescent properties, fluorophore binding affinities, and salt dependence. Also disclosed are corresponding fluorophores, with selected fluorophores evidencing high cellular permeability. The aptamer's high fluorophore affinities, the high brightness of the bound complexes, and their thermal and salt stability, provide distinct aspects of the disclosed aptamers.
Type:
Grant
Filed:
April 23, 2018
Date of Patent:
September 6, 2022
Assignees:
Centre National De La Recherche, Scientifique Université De Strasbourg, Simon Fraser University, The United States of America, As Represented by The Secretary, Department of Health and Human Services
Inventors:
Michael Ryckelynck, Alexis Autour, Peter Unrau, Elena Dolgosheina, Sunny Chiu Yuk Jeng, Shanker Shyam Sundhar Panchapakesan, Amir Abdolahzadeh, Razvan Cojocaru, Adrian Ferré D'Amaré, Robert Trachman
Abstract: Systems and methods for three-dimensional fluorescence polarization excitation that generates maps of positions and orientation of fluorescent molecules in three or more dimensions are disclosed.
Type:
Grant
Filed:
May 31, 2018
Date of Patent:
August 30, 2022
Assignee:
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Inventors:
Hari Shroff, Abhishek Kumar, Shalin B. Mehta, Patrick Jean-La Riviere, Rudolf Oldenbourg, Yicong Wu, Talon Chandler
Abstract: The present invention generally relates to compositions and methods for treating or preventing an endoplasmic reticulum stress disorder in subjects, including compositions and methods for treating or preventing Wolfram syndrome. The present invention also relates to methods for treating symptoms of neurodegenerative diseases.
Type:
Grant
Filed:
March 6, 2018
Date of Patent:
August 30, 2022
Assignees:
Washington University, The United States of America, As Represented by the Secretary, Department of Health and Human Services
Inventors:
Fumihiko Urano, Jana Mahadevan, Amy Clark, Ajit Jadhav, David Maloney, Brandon Harvey, Shyh-ming Yang, Mark Henderson
Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA.
Type:
Grant
Filed:
December 16, 2017
Date of Patent:
August 23, 2022
Assignees:
The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College, Rutgers, The State University of New Jersey, Skolkovo Institute of Science and Technology, The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Konstantin Severinov, Feng Zhang, Yuri I. Wolf, Sergey Shmakov, Ekaterina Semenova, Leonid Minakhin, Kira S. Makarova, Eugene Koonin, Silvana Konermann, Julia Joung, Jonathan S. Gootenberg, Omar O. Abudayyeh, Eric S. Lander
Abstract: Multi-dimensional spectra associated with a specimen are reconstructed using lower dimensional spectra as constraints. For example, a two-dimensional spectrum associated with diffusivity and spin-lattice relaxation time is obtained using one-dimensional spectra associated with diffusivity and spin-lattice relaxation time, respectively, as constraints. Data for a full two dimensional spectrum are not acquired, leading to significantly reduced data acquisition times.
Type:
Grant
Filed:
August 11, 2017
Date of Patent:
August 16, 2022
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Abstract: Synthetic polynucleotides encoding human propionyl-CoA carboxylase alpha (synPCCA) and exhibiting augmented expression in cell culture and/or in a subject are described herein. Adeno-associated viral (AAV) gene therapy vectors encoding synPCCA successfully rescued the neonatal lethal phenotype displayed by propionyl-CoA carboxylase alpha (Pcca?/?) deficient mice, lowered circulating methylcitrate levels in the treated animals, and resulted in prolonged hepatic expression of the product of the synPCCA transgene in vivo.
Type:
Application
Filed:
June 26, 2020
Publication date:
August 11, 2022
Applicant:
The United States of America,as represented by the Secretary,Department of Health and Human Services
Abstract: The present disclosure relates to polypeptides that specifically bind to Dengue virus non¬structural protein 1, including antibodies and fragments thereof. The antibody or antigen-binding fragment thereof may specifically bind Dengue virus (DENV) serotype 4 and include: a heavy chain variable region that comprises at least one CDR amino acid sequence selected from the group consisting of: SGYNWH, YIH YS GGTN YNPS LKS, RTGTVPFAY, SYVMH, YLNPYNDDTKYNEKFKG, and GPPYALDY. The present disclosure further relates to methods of producing the polypeptides of the present disclosure, methods of diagnosing DENV, and methods of treating a DENV infection.
Type:
Grant
Filed:
June 22, 2017
Date of Patent:
August 9, 2022
Assignee:
The United States of America, as Represented By The Secretary, Department of Health and Human Services
Inventors:
Elizabeth Anne Hunsperger, Tesfaye Gelanew Taye
Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines,
Type:
Grant
Filed:
November 19, 2020
Date of Patent:
August 2, 2022
Assignees:
The United States of America, as represented by the Secretary, Department of Health and Human Services, The Government of the United States, as Represented by The Secretary of The Army
Inventors:
Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney
Abstract: An embodiment of the invention provides a method of promoting regression of cancer in a mammal comprising obtaining a tumor tissue sample from the mammal; culturing the tumor tissue sample in a first gas permeable container containing cell medium therein; obtaining tumor infiltrating lymphocytes (TIL) from the tumor tissue sample; expanding the number of TIL in a second gas permeable container containing cell medium therein using irradiated allogeneic feeder cells and/or irradiated autologous feeder cells; and administering the expanded number of TIL to the mammal. Methods of obtaining an expanded number of TIL from a mammal for adoptive cell immunotherapy are also provided.
Type:
Grant
Filed:
December 6, 2018
Date of Patent:
August 2, 2022
Assignees:
The United States of America, as represented by the Secretary, Department of Health and Human Services, Wilson Wolf Manufacturing Corporation
Inventors:
Steven A. Rosenberg, Mark E. Dudley, David Stroncek, Marianna Sabatino, Jianjian Jin, Robert Somerville, John R. Wilson
Abstract: Methods and kits for preparing re-usable single cells are described. Cell components are anchored using a nano-scale scaffold to create a re-usable single cell. The nano-scale scaffold may be a polyacrylamide nano-scale scaffold. Methods to determine modifications of the genome, transcriptome, or epigenome are described.
Type:
Grant
Filed:
May 4, 2018
Date of Patent:
August 2, 2022
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Abstract: Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.
Type:
Application
Filed:
May 4, 2020
Publication date:
July 21, 2022
Applicant:
The United States of America,as represented by the Secretary,Department of Health and Human Services
Inventors:
Robert Seder, Lawrence Wang, Rachel Vistein, Joseph Francica
Abstract: A virtual 511 KeV attenuation map is generated from CT data. Spectral or multiple energy CT is used to more accurately extrapolate the 511 KeV attenuation map. Since spectral or multiple energy CT may allow for material decomposition and/or due to additional information in the form of measurements at different energies, the modeling used to generate the 511 KeV attenuation map may better account for all materials including high density material. The extrapolated 511 KeV attenuation map may more likely represent actual attenuation at 511 KeV without requiring extra scanning using a 511 KeV source external to the patient. The virtual 511 KeV attenuation map (e.g., CT data at 511 KeV) may provide more accurate PET image reconstruction.
Type:
Grant
Filed:
September 30, 2019
Date of Patent:
July 19, 2022
Assignees:
Siemens Healthcare GmbH, The United States of America, as represented by the Secretary, Department of Health and Human Services